Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer

Inclusion Criteria

• •Histologic diagnosis of breast cancer with documentation of ER/PR/HER2 status
• •Radiographic evidence of stage IV extracranial disease enrolled within 60 days of diagnosis or starting first line therapy. HR+/HER2- patients may be enrolled within 60 days of starting 2nd line therapy as well.
• •HR+ will be defined as ER and/or PR \> 10%. To be classified as HER2+ disease, overexpression of HER2 by either IHC or in-situ hybridization is necessary as defined by the ASCO / CAP Guidelines41. Triple negative will be classified as ER and PR \<10% and HER2-.
• •Age ≥ 18
• •Life expectancy ≥ 6 months
• •Eastern Cooperative Oncology Group performance status ≤ 2
• •Patients must be able to understand and the willingness to sign an informed consent for study procedures
• •Stated willingness to comply with all study procedures and availability for the duration of the study